"rationale","uuid:ID","id","versionIdentifier","instanceType"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","143ce23d-20b1-4e12-9033-d20d0f12a9d9","StudyVersion_1","2","StudyVersion"
